Alnylam starts Phase 2 DS-AD trial and completes CAA enrollment for mivelsiran
The company also reported updated Phase 1 early-onset Alzheimer’s data showing no increased ARIA risk and outlined ongoing Phase 1 work for tau-targeting ALN-5288 with Regeneron.